News · Brain & Mental Health
A protein on breast cancer cells calmed the brain's immune cells and helped tumors settle there, in mice
Triple negative breast cancer reaches the brain more often than most. Work in mice and human tissue points at one protein doing two jobs: driving the cells onward and quietening the brain's defenses.
- The cause-and-effect work was done in mice and cell lines; the human part is tissue, not patients.
- Triple negative breast cancer is the subtype most likely to spread to the brain.
- A protein called SIRP-alpha was higher in patients' brain metastases and in brain-seeking tumor cells.
- It appeared to blunt the brain's resident immune cells, letting tumor cells escape notice.
- Blocking it shrank brain lesions in mice. No treatment for people exists on this evidence.
The brain is supposed to be a difficult place for a tumor to reach. It has its own border control and its own resident immune cells, and most cancer cells that arrive there do not survive the welcome. Triple negative breast cancer reaches it anyway, more often than most other breast cancers, and once it does the outlook is poor.
A study in Neuro-Oncology, run in mice and human tissue, proposes an explanation that is unsettling in its economy. One protein on the cancer cell appears to do two jobs at once: make the cell more likely to travel, and make the brain less likely to object.
What makes triple negative breast cancer harder to treat?
Most breast cancers carry receptors that drugs can aim at, for estrogen, progesterone or the HER2 protein. Triple negative tumors have none of the three, which removes the treatments that work best and leaves chemotherapy doing most of the work. The authors state the problem plainly: this subtype requires new treatment strategies due to poor responses to current therapies.
Spread to the brain is part of what makes it feared. MedlinePlus notes that if the cancer spreads outside the breast, it is still called breast cancer, and treated as such, which is why a breast tumor in the brain is a breast cancer problem rather than a brain cancer one.
Which protein was found on the tumor cells?
SIRP-alpha, a signaling protein normally discussed in a completely different context. On immune cells it functions as a brake, part of the system that stops them attacking the body’s own tissue. It is the target of a class of cancer drugs designed to release that brake.
Finding it on the cancer cells themselves is the turn here. Human single-cell data showed that its levels increased in malignant triple negative breast cancer cells, and the team observed that it is upregulated in patient breast-to-brain metastatic lesions. Cells selected for their ability to seed the brain carried more of it than their parent cells.
How SIRP-alpha helped tumors settle in the brain
Two mechanisms, running in parallel. Inside the cancer cell, the protein drives a change in how the cell’s mitochondria behave: the paper reports that it upregulates mitochondrial fission and induces metastasis through a SHP2 signaling pathway. Mitochondria splitting into smaller units is a change associated with cells that move.
Outside the cell, something more interesting happens to the brain. Spatial analysis pointed to fibronectin, a scaffolding protein whose production the tumor influences, and the team found that fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, allowing cancer to escape microglial immunosurveillance.
“One of the most intriguing findings was that the tumor cells appeared to weaken the response of the brain’s immune cells,” said David R. Soto-Pantoja of Wake Forest University School of Medicine, the corresponding author. His summary of the whole result: “Our findings suggest that SIRP-alpha helps make tumor cells more aggressive while also changing the brain environment in ways that help those cells survive.”
What happened when the protein was blocked
The experiment that matters most is the one that removes it. In mouse models, overexpression of the protein in cancer cells significantly increased systemic metastasis, and running it the other way, inhibition reduced brain metastatic lesions in mouse metastasis models.
That is the shape of evidence a drug target needs: more of the protein, more spread; less of the protein, fewer lesions. It is also, at this stage, entirely a mouse result.
What mouse models cannot show about brain metastasis
The brain-metastasis model involved injecting brain-seeking tumor cells into the circulation, which reproduces the settling step but skips everything a real cancer does to get there. Mouse immune systems differ from human ones in ways that have repeatedly flattered cancer immunology results before they reached patients.
The human component is observational. Patient tissue showed the protein raised in brain lesions, but tissue cannot say whether that came before the metastasis or after it.
And nothing was tested in a person. The MedicalXpress account of the work notes that more research is needed before the approach can be evaluated in patients, which is the accurate description of where this sits.
Why a two-sided mechanism in brain metastasis is worth following
Most metastasis research asks what the tumor cell is doing. The part of this work likely to matter is the other half: a tumor that arrives in the brain and quietens the cells whose job is to notice it.
If that holds up in people, it reframes the problem. Stopping breast cancer reaching the brain is one target, and keeping the brain’s own defenses awake once it gets there is a different one, reachable by different drugs. Soto-Pantoja’s framing of the stakes is the honest place to end: “The biology of brain metastasis is incredibly complex, and we urgently need better ways to prevent and treat it.”
People also ask
What did the study find?
Human single-cell data showed SIRP-alpha levels increased in malignant triple negative breast cancer cells, and the protein was upregulated in patient breast-to-brain metastatic lesions. In mice, overexpressing it significantly increased systemic metastasis, and inhibiting it reduced brain metastatic lesions. The team traced the effect through mitochondrial fission and through fibronectin-induced tolerance in microglia.
What is triple negative breast cancer?
A subtype whose cells lack the three receptors most breast cancer treatments target, which is why it has fewer treatment options and a worse outlook. The authors open by noting it requires new treatment strategies due to poor responses to current therapies.
What are microglia?
The brain's own immune cells. They patrol brain tissue, clear debris and attack what does not belong, which makes them the first line a spreading tumor cell has to get past.
What is SIRP-alpha?
A signaling protein best known on immune cells, where it acts as a brake that stops them attacking healthy tissue. The novelty here is finding it on the cancer cells themselves and showing it does something for the tumor.
Was this tested in patients?
No. Patient tissue was examined, but every experiment that manipulated the protein was done in cells or mice. The authors say more work is needed before the approach can be evaluated in patients.
Does this change treatment now?
No. There is no therapy based on this and nothing here should alter anyone's care. Treatment decisions for triple negative breast cancer belong with an oncologist. This is general information rather than medical advice.